For the first time World Diabetes Day was held by the International Diabetes Federation − IDF and the World Health Organization (WHO − World Health Organization) −14 November 1991 to coordinate the fight against diabetes worldwide.
Find out in the article on estet-portal.com what discoveries and drugs will help to effectively prevent cardiovascular complications in patients with diabetes in the near future.
- Statistics and consequences of the spread of diabetes
- Safety of diabetes treatment in cardiovascular pathology
- Metformin efficacy study resultsa
Statistics and consequences of the spread of diabetes
Diabetes − this is a chronic condition in which the pancreas does not produce enough insulin or the body cannot use the insulin it produces effectively.
Insulin − it is a hormone that regulates blood glucose levels.
Follow us on Instagram!
More than 400 million people worldwide are living with diabetes and it is predicted that by 2050 the number of patients with this pathology will increase by 48% in the world.
The prevalence of diabetes has increased by half over the past 10 years.
Type 1 diabetes accounts for 6.5% of all cases.
Read also: Advances in genetic engineering in the treatment of diabetes
Nearly 3% of primary disability among the adult population is a consequence of this diseasei.
Safety of treatment of diabetes mellitus in cardiovascular pathology
Left ventricular hypertrophy (LVH) is an independent predictor of mortality and is very common in patients with ischemic heart disease (CHD), which is often seen in patients with diabetes diabetes, even in the absence of arterial hypertension.
LVH is a common condition, found in about a third of patients with CAD.
It is important to note that LVH is one of the prominent predictors of CAD after age and disease severity.
Not all hypoglycemic drugs are safe for patients with cardiovascular disease.
Metformin was the first and for a long time the only hypoglycemic drug that had a beneficial effect on the heart and did not worsen the cardiovascular prognosis in patients with diabetes mellitus.
Read also: What contributes to the development of type 1 diabetes
However, its effects in non-diabetic patients remain largely unexplored.
In this connection, a double-blind, placebo-controlled study MET-REMODEL (Metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes), the purpose of which was to evaluate the effect of metformin on the mass of the left ventricular (LV) myocardium in patients with coronary artery disease who have insulin resistance and / or prediabetesno.
Metformin efficacy study results
The study included 68 patients with a mean age of 65 years.
Read also: What effects can testosterone therapy have in women
The patients were divided into two groups:
- metformin (2000 mg/day);
- Placebo group.
The study continued for 12 months, the primary point of the study was change in LV myocardial mass.
The images at the beginning and at the end of the study were obtained on a magnetic resonance imaging scanner.
By the end of the study, there was a significant reduction in LV mass index in the metformin subgroup compared with placebo.
In addition, the use of metformin significantly reduced body weight and subcutaneous fat, as well as systolic blood pressure.
Glycated hemoglobin and resistance index were not significantly different between the metformin and placebo groups at the end of the study.
Thus, it has been found that metformin can reduce the LV mass index in patients with coronary artery disease who are at high risk of developing diabetes.
The authors believe that the decrease in blood pressure or body weight in the metformin group may have been the reason for this effect.
Read also: Foot ulcer in diabetes mellitus: rational antibiotic therapy
According to the authors, these results may warrant large trials with hard endpoints on the cardiovascular efficacy of metformin in patients at risk of developing diabetes mellitus or established prediabetes.
More interesting videos on our YouTube-channel!
Share:
Add a comment